Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02749968 · ClinicalTrials.gov registry record · Phase 2
Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma
A Phase 2 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT02749968 is a Phase 2 study that has completed, run by University of Cincinnati. The registered enrollment target is 100 participants.
The verdict
NCT02749968, a Phase 2 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is a study of liposomal bupivacaine for pain control in patients with blunt chest wall trauma.
Interventions
- DRUG Liposomal bupivacaine
- DRUG 0.9% sodium chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-03-09 |
| Est. Completion | 2021-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02749968
The ClinicalTrials.gov registry entry for NCT02749968 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal bupivacaine is the first listed.
NCT02749968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02749968 about?
NCT02749968 is a clinical study titled "Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma". This is a study of liposomal bupivacaine for pain control in patients with blunt chest wall trauma.
What is the current status of trial NCT02749968?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2018-03-09. Estimated completion is 2021-01-01.
What interventions are being tested in trial NCT02749968?
The interventions under investigation include: Liposomal bupivacaine (DRUG), 0.9% sodium chloride (DRUG).
Who is sponsoring clinical trial NCT02749968?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.